Last reviewed · How we verify
BRM424 Ophthalmic Solution - Dose1
BRM424 Ophthalmic Solution - Dose1 is a Topical anti-inflammatory Small molecule drug developed by BRIM Biotechnology Inc.. It is currently in Phase 2 development for Treatment of dry eye disease.
BRM424 Ophthalmic Solution is a topical anti-inflammatory agent.
BRM424 Ophthalmic Solution is a topical anti-inflammatory agent. Used for Treatment of dry eye disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BRM424 Ophthalmic Solution - Dose1 |
|---|---|
| Sponsor | BRIM Biotechnology Inc. |
| Drug class | Topical anti-inflammatory |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
BRM424 Ophthalmic Solution works by reducing inflammation in the eye, which can help alleviate symptoms of certain eye conditions. The exact molecular target is not publicly disclosed, but it is believed to involve the inhibition of pro-inflammatory pathways.
Approved indications
- Treatment of dry eye disease
Common side effects
- Eye irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRM424 Ophthalmic Solution - Dose1 CI brief — competitive landscape report
- BRM424 Ophthalmic Solution - Dose1 updates RSS · CI watch RSS
- BRIM Biotechnology Inc. portfolio CI
Frequently asked questions about BRM424 Ophthalmic Solution - Dose1
What is BRM424 Ophthalmic Solution - Dose1?
How does BRM424 Ophthalmic Solution - Dose1 work?
What is BRM424 Ophthalmic Solution - Dose1 used for?
Who makes BRM424 Ophthalmic Solution - Dose1?
What drug class is BRM424 Ophthalmic Solution - Dose1 in?
What development phase is BRM424 Ophthalmic Solution - Dose1 in?
What are the side effects of BRM424 Ophthalmic Solution - Dose1?
Related
- Drug class: All Topical anti-inflammatory drugs
- Manufacturer: BRIM Biotechnology Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of dry eye disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing